Literature DB >> 24014299

Critical signal transduction pathways in CLL.

Asish K Ghosh1, Neil E Kay.   

Abstract

Receptor tyrosine kinases (RTKs) are cell-surface transmembrane receptors that contain regulated kinase activity within their cytoplasmic domain and play a critical role in signal transduction in both normal and malignant cells. Besides B cell receptor (BCR) signaling in chronic lymphocytic leukemia (CLL), multiple RTKs have been reported to be constitutively active in CLL B cells, resulting in enhanced survival and resistance to apoptosis of the leukemic cells induced by chemotherapeutic agents. In addition to increased plasma levels of various types of cytokines/growth factors in CLL, we and others have detected that CLL B cells spontaneously produce multiple cytokines in vitro which may constitute an autocrine loop of RTK activation on the leukemic B cells. Moreover, aberrant expression and activation of non-RTKs, for example, Src/Syk kinases, induce resistance of the leukemic B cells to therapy. Based on current available knowledge, we detailed the impact of aberrant activities of various RTKs/non-RTKs on CLL B cell survival and the potential of using these signaling components as future therapeutic targets in CLL therapy.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24014299      PMCID: PMC3918736          DOI: 10.1007/978-1-4614-8051-8_10

Source DB:  PubMed          Journal:  Adv Exp Med Biol        ISSN: 0065-2598            Impact factor:   2.622


  156 in total

1.  Tyro-3 family receptors are essential regulators of mammalian spermatogenesis.

Authors:  Q Lu; M Gore; Q Zhang; T Camenisch; S Boast; F Casagranda; C Lai; M K Skinner; R Klein; G K Matsushima; H S Earp; S P Goff; G Lemke
Journal:  Nature       Date:  1999-04-22       Impact factor: 49.962

2.  Functional map and domain structure of MET, the product of the c-met protooncogene and receptor for hepatocyte growth factor/scatter factor.

Authors:  Ermanno Gherardi; Mark E Youles; Ricardo N Miguel; Tom L Blundell; Luisa Iamele; Julian Gough; Abhishek Bandyopadhyay; Guido Hartmann; P Jonathan G Butler
Journal:  Proc Natl Acad Sci U S A       Date:  2003-10-03       Impact factor: 11.205

3.  Bone biopsy derived marrow stromal elements rescue chronic lymphocytic leukemia B-cells from spontaneous and drug induced cell death and facilitates an "angiogenic switch".

Authors:  Neil E Kay; Tait D Shanafelt; Ann K Strege; Yean K Lee; Nancy D Bone; Azra Raza
Journal:  Leuk Res       Date:  2007-01-22       Impact factor: 3.156

Review 4.  Defining the role of the JAK-STAT pathway in head and neck and thoracic malignancies: implications for future therapeutic approaches.

Authors:  Stephen Y Lai; Faye M Johnson
Journal:  Drug Resist Updat       Date:  2010-05-14       Impact factor: 18.500

Review 5.  Emerging role of kinase-targeted strategies in chronic lymphocytic leukemia.

Authors:  Adrian Wiestner
Journal:  Blood       Date:  2012-08-08       Impact factor: 22.113

6.  Alternative splicing of the human VEGFGR-3/FLT4 gene as a consequence of an integrated human endogenous retrovirus.

Authors:  D C Hughes
Journal:  J Mol Evol       Date:  2001-08       Impact factor: 2.395

7.  Dominant-negative inhibition of the Axl receptor tyrosine kinase suppresses brain tumor cell growth and invasion and prolongs survival.

Authors:  Peter Vajkoczy; Pjotr Knyazev; Andrea Kunkel; Hans-Holger Capelle; Sandra Behrndt; Hendrik von Tengg-Kobligk; Fabian Kiessling; Uta Eichelsbacher; Marco Essig; Tracy-Ann Read; Ralf Erber; Axel Ullrich
Journal:  Proc Natl Acad Sci U S A       Date:  2006-04-03       Impact factor: 11.205

8.  Insulin-like growth factor-I regulates pro-B cell differentiation.

Authors:  K S Landreth; R Narayanan; K Dorshkind
Journal:  Blood       Date:  1992-09-01       Impact factor: 22.113

9.  Identification of FGFR4-activating mutations in human rhabdomyosarcomas that promote metastasis in xenotransplanted models.

Authors:  James G Taylor; Adam T Cheuk; Patricia S Tsang; Joon-Yong Chung; Young K Song; Krupa Desai; Yanlin Yu; Qing-Rong Chen; Kushal Shah; Victoria Youngblood; Jun Fang; Su Young Kim; Choh Yeung; Lee J Helman; Arnulfo Mendoza; Vu Ngo; Louis M Staudt; Jun S Wei; Chand Khanna; Daniel Catchpoole; Stephen J Qualman; Stephen M Hewitt; Glenn Merlino; Stephen J Chanock; Javed Khan
Journal:  J Clin Invest       Date:  2009-10-05       Impact factor: 14.808

Review 10.  Hepatocyte growth factor, its receptor, and their potential value in cancer therapies.

Authors:  Wen G Jiang; Tracey A Martin; Christian Parr; Gaynor Davies; Kunio Matsumoto; Toshikazu Nakamura
Journal:  Crit Rev Oncol Hematol       Date:  2005-01       Impact factor: 6.312

View more
  5 in total

Review 1.  Molecular basis of chronic lymphocytic leukemia diagnosis and prognosis.

Authors:  Mohammad Shahjahani; Javad Mohammadiasl; Fatemeh Noroozi; Mohammad Seghatoleslami; Saeid Shahrabi; Fakhredin Saba; Najmaldin Saki
Journal:  Cell Oncol (Dordr)       Date:  2015-01-07       Impact factor: 6.730

2.  FAS-antisense 1 lncRNA and production of soluble versus membrane Fas in B-cell lymphoma.

Authors:  L Sehgal; R Mathur; F K Braun; J F Wise; Z Berkova; S Neelapu; L W Kwak; F Samaniego
Journal:  Leukemia       Date:  2014-04-03       Impact factor: 11.528

3.  Axl activates fibroblast growth factor receptor pathway to potentiate survival signals in B-cell chronic lymphocytic leukemia cells.

Authors:  S Sinha; J Boysen; M Nelson; S L Warner; D Bearss; N E Kay; A K Ghosh
Journal:  Leukemia       Date:  2015-11-24       Impact factor: 11.528

Review 4.  Molecular Interactions Between Innate and Adaptive Immune Cells in Chronic Lymphocytic Leukemia and Their Therapeutic Implications.

Authors:  Muhammad Haseeb; Muhammad Ayaz Anwar; Sangdun Choi
Journal:  Front Immunol       Date:  2018-11-26       Impact factor: 7.561

5.  Neurotensin receptor type 2 protects B-cell chronic lymphocytic leukemia cells from apoptosis.

Authors:  A Abbaci; H Talbot; S Saada; N Gachard; J Abraham; A Jaccard; D Bordessoule; A L Fauchais; T Naves; M O Jauberteau
Journal:  Oncogene       Date:  2017-10-23       Impact factor: 9.867

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.